Result of AGM

RNS Number : 5259G
GlaxoSmithKline PLC
07 May 2014
 



 GlaxoSmithKline plc - Result of AGM

 

GlaxoSmithKline plc (GSK) announces that at its Annual General Meeting (AGM) today, all resolutions were passed by shareholders.

 

GlaxoSmithKline AGM Poll Results

 

The following table shows the votes cast for each resolution:

 

Resolution

Total votes for*

%

Total votes against

%

Total votes cast

Votes withheld**

1

Adoption of Directors' Report and Financial Statements

3,547,982,735

98.85

41,278,849

1.15

3,589,261,584

10,176,355

2

Approval of the Remuneration Report

3,377,865,669

98.52

50,641,769

1.48

3,428,507,438

170,934,805

3

 

Approval of the Directors' Remuneration Policy

3,408,815,630

97.42

90,250,943

2.58

3,499,066,573

100,375,670

4

Re-election of  Sir Christopher Gent

3,439,528,694

95.90

147,149,979

4.10

3,586,678,673

12,768,786

5

Re-election of Sir Andrew Witty

3,578,767,397

99.72

10,010,466

0.28

3,588,777,863

10,669,596

6

Re-election of Professor Sir Roy Anderson

3,579,231,977

99.74

9,439,851

0.26

3,588,671,828

10,774,711

7

Re-election of Dr Stephanie Burns

3,576,112,095

99.65

12,610,100

0.35

3,588,722,195

10,724,344

8

Re-election of Stacey Cartwright

3,568,976,499

99.45

19,694,382

0.55

3,588,670,881

10,775,379

9

Re-election of Simon Dingemans

3,542,608,802

98.72

45,996,505

1.28

3,588,605,307

10,841,886

10

Re-election of Lynn Elsenhans

3,585,307,313

99.91

3,293,782

0.09

3,588,601,095

10,845,444

11

Re-election of Judy Lewent

3,549,394,841

98.91

39,226,163

1.09

3,588,621,004

10,825,535

12

Re-election of Sir Deryck Maughan

3,561,179,474

99.24

27,416,814

0.76

3,588,596,288

10,850,250

13

Re-election of Dr Daniel Podolsky

3,579,219,741

99.74

9,358,778

0.26

3,588,578,519

10,868,020

14

Re-election of Dr Moncef Slaoui

3,574,560,380

99.61

14,055,744

0.39

3,588,616,124

10,831,335

15

Re-election of Tom de Swaan

 

3,525,650,902

98.30

61,002,251

1.70

3,586,653,153

12,793,386

16

Re-election of Jing Ulrich

3,585,201,858

99.91

3,322,988

0.09

3,588,524,846

10,921,427

17

Re-election of Hans Wijers

3,280,229,504

91.57

301,809,653

8.43

3,582,039,157

17,407,382

18

Re-appointment of auditors

3,503,022,193

98.93

37,982,934

1.07

3,541,005,127

58,441,412

19

Remuneration of auditors

3,520,845,776

99.32

23,984,857

0.68

3,544,830,633

54,615,906

20

Authority for the company to make donations to political organisations and incur political expenditure

3,498,414,617

97.67

83,465,800

2.33

3,581,880,417

17,567,042

21

Authority to allot shares

3,478,465,018

97.01

107,214,629

2.99

3,585,679,647

13,766,892

22

Disapplication of pre-emption rights***

3,497,328,599

97.60

85,983,069

2.40

3,583,311,668

16,135,585

23

Authority for the company to purchase its own shares***

3,578,605,038

99.73

9,538,332

0.27

3,588,143,370

11,302,119

24

Exemption from statement of senior statutory auditor's name

3,568,553,870

99.57

15,538,722

0.43

3,584,092,592

15,354,867

25

Authorise reduced notice of a general meeting other than an AGM***

3,204,747,061

89.37

381,205,594

10.63

3,585,952,655

13,494,803

 

Sir Robert Wilson did not stand for re-election as a Director, and has stepped down from the Board with effect from the conclusion of the AGM.

 

The following table provides further relevant information:

 


 

GlaxoSmithKline's

Fourteenth AGM

(2014)

 

 

GlaxoSmithKline's

Thirteenth AGM

(2013)

 

Issued share capital

(excluding Treasury Shares)

4,861,007,167

4,922,724,518

Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares)

74.05%

76.50%

Total shareholder population

140,792

144,196

Total number of proxies lodged

8,333

8,931

% of shareholders who lodged proxies

5.92%

6.19%

Number of shareholders, corporate representatives and proxies who attended the AGM

429

442

 

 

In accordance with Listing Rule 9.6.2, copies of the resolutions that do not constitute ordinary business at an annual general meeting will be submitted to the UK Listing Authority and will in due course be available for inspection at www.morningstar.co.uk/uk/NSM and on the company's website at http://www.gsk.com/investors/shareholder-information/annual-general-meeting.html

 

Notes:

*           Includes discretionary votes.

**         A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" a resolution.

***        Indicates Special Resolutions requiring a 75% majority.

 

 

V A Whyte

Company Secretary

7 May 2014

 

 

GSK enquiries:




UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502

(London)


Simon Steel

+44 (0) 20 8047 5502

(London)


David Daley

+44 (0) 20 8047 5502

(London)


Catherine Hartley

+44 (0) 20 8047 5502

(London)


Sarah Spencer

+44 (0) 20 8047 5502

(London)





US Media enquiries:

Stephen Rea

+1 215 751 4394

(Philadelphia)


Melinda Stubbee

+1 919 483 2510

(North Carolina)


Mary Anne Rhyne

+1 919 483 0492

(North Carolina)


Emily Beamer

+1 215 751 6622

(Philadelphia)


Jennifer Armstrong

+1 215 751 5664

(Philadelphia)





Analyst/Investor enquiries:

Ziba Shamsi

+44 (0) 20 8047 5543

(London)


Kirsty Collins (SRI & CG)

+44 (0) 20 8047 5534

(London)


Tom Curry

+ 1 215 751 5419

(Philadelphia)


Gary Davies

+44 (0) 20 8047 5503

(London)


James Dodwell

+44 (0) 20 8047 2406

(London)


Jeff McLaughlin

+1 215 751 7002

(Philadelphia)


Lucy Singah

+44 (0) 20 8047 2248

(London)

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGQKODDABKDFPK

Companies

GSK (GSK)
UK 100

Latest directors dealings